Cardiovascular risk factor appraisal art or science?
|
|
- Maria Nicholson
- 5 years ago
- Views:
Transcription
1 Cardiovascular risk factor appraisal art or science? Prof. Philip MacCarthy BSc MBChB (Hons) PhD FRCP Consultant Cardiologist Bupa Cromwell Hospital Clinics: Wednesday & Friday PM/Evening
2 What are we trying to achieve?
3 CVD Mortality in England (all <75 yrs) BHF Heart Stats (2012)
4 Causes of Death (England, <75 yrs) (Source: Living Well for Longer [ONS data], 2013) Source: statbase/product.asp?vlnk=6725
5 CVD.. 200k deaths pa (1:3 of all) 4.9m adults have CVD (11.7% of population) 1.4m hospital admissions in 2010/11 65% were patients under 75 yrs >50% were emergencies CVD costs NHS & UK economy 30bn pa. Prevalence increases with deprivation - Inequalities Services for the prevention of CV Disease NICE Commissioning Guide 45. March 2012
6 UK causes of Years of Life Lost (both sexes, all ages) Global Burden of Disease Study. Lancet 2013;381: diseases and injuries & 67 risk factors
7 History
8 The Framingham Heart Study Data collection started in 1948 Bi-annual follow up First CVD risk equation: Truett et al > 20 groups of regression equations between 1967 and 2008 Modified Anderson et al 1991 used in UK
9 Framingham - Anderson Data collected men and women followed up for 12 years Six regression equations published in 1991
10 Risk factors used to calculate the Anderson Framingham risk score -age and sex -diastolic and systolic BP -total:hdl cholesterol ratio -diabetes (Y/N) -cigarette smoking (Y/N) -LVH (Y/N) Absolute CVD Risk over 10 years
11 Different versions and coloured charts New Zealand cardiovascular risk prediction charts
12 Limitations of Framingham BP treatment Family History Deprivation Ethnicity Generalisability Statistical validity Face validity Improvements were needed
13 A new era of CV risk prediction
14 SCORE Systematic Coronary Risk Evaluation ,178 men and women from 12 European cohort studies
15 SCORE better than Framingham? BP treatment Family History Deprivation Ethnicity Generalisability? Statistical validity Face validity SCORE No No No No Yes No
16 ASSIGN - ASSessing cardiovascular risk, using SIGN guidelines Scottish Heart and Health Extended Cohort (SHHEC) 6540 men, 6757 women Classic risk factors plus Deprivation Family history Shifts treatment towards the socially deprived compared to Framingham
17 ASSIGN better than Framingham? SCORE ASSIGN BP treatment No No Family History No Yes Deprivation No Yes Ethnicity No No Generalisability?? Statistical validity Yes Yes Face validity No No
18 The evolution of QRISK
19 QRISK1 and QRISK2 Electronic patient record Cohort analysis based on large validated GP database (QResearch) Contains individual patient level data 15 year study period 1993 to 2008 First diagnosis of CVD (including CVD death) QRISK1 Deprivation Family History BMI On BP treatment NO Ethnicity
20 QRISK 1 QRISK algorithm derived from Derivation cohort 1.28 million patients Validated in the Validation cohort 0.61 million patients QRISK out-performed Framingham and ASSSIGN
21 QRISK1 - better than Framingham? SCORE ASSIGN QRISK1 BP treatment No No Yes Family History No Yes Yes Deprivation No Yes Yes Ethnicity No No No Generalisability?? Yes Statistical validity Yes Yes Yes Face validity No No Yes
22 QRISK2 Included ONS deaths linkage Included additional variables 2.3 million people (>16 million person yrs) Self-assigned ethnicity
23 Age-standardised incidence of CVD by deprivation Q1 (affluent) Q2 Q3 Q4 Q5 (deprived) 0 females males
24 Age-standardised incidence of CVD by Ethnicity per 1000 pyrs % White Indian Pakistani Bangladeshi Other Asian Black Caribbean 5 Black African Chinese 0 Females Males Other
25 Framingham over-predicts QRISK underpredicts Collins and Altman, BMJ 2009;339:2584
26 QRISK2 better than Framingham? SCORE ASSIGN QRISK1 QRISK2 BP treatment No No Yes Yes Family History No Yes Yes Yes Deprivation No Yes Yes Yes Ethnicity No No No Yes Reproducibility Yes Yes Yes Yes Generalisability?? Yes Yes Statistical validity Yes Yes Yes Yes Face validity No No Yes Yes
27 How to apply QRisk2 in practice
28 How to apply QRisk2 in practice
29 Future developments of QRISK2 A living evidence base
30 JBS3
31 Heart 2014;100:ii1-ii67
32 NICE guidance for statin use
33 Case study 1 Young female with significant risk factors Effect of intensive risk factor modification 35-year-old female smoker Systolic BP of 160mmHg TC of 7.0mmol/L, HDL of 1.4mmol/L (non-hdl of 5.6mmol/L) Family history of premature CVD
34 Estimated average survival without a CV event
35 Estimated average survival without a CV event
36 Effect of intensive risk factor modification
37 Effect of intensive risk factor modification
38 Shortfalls of CV risk scores Not tailored to individual patients Differing views on lifestyle/medications Not completely accurate Is 10yr risk the correct metric? Should be used in the context of clinical common sense!
39 Further refinement of CV risk Functional testing eg. Exercise ECG/echo Cardiac CT Ca++ scoring/ct angiography PLAC test Genetic testing Other parameters hs-crp, fibrinogen, LP(a)
40
41 Lipoprotein-associated phospholipase A2 PLAC test
42
43 Predictive value of Lp-PLA2 activity
44
45
46 Cardiac CT Calcium scoring Detrano et al, NEJM 2008;358:1336
47
48 Case Study 2 44yr old Asian Goldman Sachs Executive Slim. Asymptomatic. Non-diabetic. Strong FHx of premature IHD Total cholesterol 7.8 LDL 5.46 HDL 1.23 Non-smoker BP 100/60
49 JBS3
50 Case study 2 Rx: Atorvastatin 10mg od
51 CT coronary angiography
52 Case study 3 50yr old man. Management Consultant. Asymptomatic CV RF: Strong FHx of IHD (Father/Uncle CABG, Mother PCI), HTn on Lisinopril Total Cholesterol: 5.5 HDL: 1.3 LDL: 3.9
53 Case study 3
54 CT Coronary Angiogram Ca++ score 48 (50-75 th centile) 50-70% stenosis in proximal LAD Stress Echocardiogram Reversible ischaemia in LAD territory
55 Physiologically-guided PCI-LAD
56 Case study 4 56yr old male. Asymptomatic. Strong FHx of IHD Father MI 61yrs Paternal GF MI 60yrs Uncle fatal MI 60yrs Total cholesterol now controlled with statin TC 4.1, LDL 2.0
57 Screening history 2014 Exercise ECG ST depression at peak workload. No symptoms CTCA Ca++ score 276. Prox LAD stenosis 2014 Invasive cor angio Moderate LMS/LAD disease 2014 Stress echo negative at good workload
58 Screening history March 2016 repeat stress echo ischaemia at high workload (12 55 ) referred to me. Invasive coronary angiogram with a view to pressure wire assessment
59 Angiogram 70% 80% 70% Distal LMS/Ostial LAD Underwent CABG x 3
60 Case study 5 The brother of Case study 4! Asymptomatic Frightened by the story of his brother asked local Cardiologist to screen him for CAD Stress echo negative at high workload. Told not to worry and take a statin (TC 4.0, LDL 2.3, HDL 1.1 on rosuvastatin 5mg) Came to me for second opinion
61 Case study 5 - screening Cardiac CT Ca++ score 932 dense calcification in LMS, prox and mid-lad. 80th centile. No angiogram performed. Invasive coronary angiogram at patient s (and brother s) insistence!
62 Coronary angiogram 95% Mid-LAD stenosis PCI LAD with drug-eluting stent
63 What do we do with asymptomatic coronary disease?
64 The FAME 2 Trial
65 FAME 2 De Bruyne et al, NEJM 2014;371:1208
66 Conclusions Cardiovascular risk predictors are useful tools but only form a framework for management Risk scores should be performed in the context of individual patients CV risk factor management can be enhanced by an individual approach and further tests (CT, PLAC) The evidence base for management of completely asymptomatic CAD is lacking
67 Thank you! How to refer? Call
QStatin Update Information
QStatin -2014 Update Information Revision History Revision date Document Version Summary of Changes 19.08.2014 V1.0 First issue. Contents 1 Purpose of document... 3 2 Rationale for regular updates of QStatin...
More informationDr Chris Ellis. Consultant Cardiologist Auckland
Dr Chris Ellis Consultant Cardiologist Auckland CVD Risk Prevention in NZ 2013 & Beyond: The Clinicians View Dr Chris Ellis Cardiologist Green Lane CVS Service, Cardiology Department, Auckland City Hospital
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationBeyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital
Beyond Framingham Prediction of cardiovascular risk Niels van Pelt Cardiologist, Middlemore Hospital Niels Bohr (Danish Physicist)1885-1962 Prediction is very difficult, especially if it's about the future
More informationValidation of QRISK2 (2014) in patients with diabetes
Validation of QRISK2 (2014) in patients with diabetes Authors Julia Hippisley-Cox Professor of Clinical Epidemiology & General Practice 1 Carol Coupland Associate Professor and Reader in Medical Statistics
More informationShould we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationKhai Pham Gia. Vietnam Cardiovascular Organization Cardiovascular Hospital. Hanoi, Vietnam. Declared no potential conflict of interest.
Khai Pham Gia Vietnam Cardiovascular Organization Cardiovascular Hospital Hanoi University of Medicine Hanoi, Vietnam Declared no potential conflict of interest. Hypertension in Patients with Coronary
More informationIschaemic Heart Disease
Ischaemic Heart Disease Katherine Rothwell Case 1 65 yr old female PMHx : Eczema, is a smoker 20/day Comes to see you complaining of central chest pain Present past few months. Comes on when gardening
More informationSupplemental tables/figures
Supplemental tables/figures Table S:Baseline variables included in calculation of QRISK and Framingham scores Ethnicity (European, Indian Pakistani, Bangladeshi, Black African, Black Caribbean) QRISK Age,
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationRichard Grocott Mason
Richard Grocott Mason What to do with a 50 year old man with chest pain? Does the pain sound cardiac? Is this a possible acute coronary syndrome? Does patient have a previous cardiac history? Natural history
More informationChief CT Technologist Pacific Radiology Christchurch. Radiologist & Director Christchurch Radiology Group Christchurch
Dr Ross Keenan Radiologist & Director Christchurch Radiology Group Christchurch Clare Stevens Chief CT Technologist Pacific Radiology Christchurch 8:30-9:25 WS #145: Non Invasive Coronary Assessment 9:35-10:30
More informationColin Edwards Cardiologist Waitemata Health and Auckland Heart Group
Colin Edwards Cardiologist Waitemata Health and Auckland Heart Group June 2015 Disclosures PFIZER LECTURE SERIES Concepts in CV Risk Assessment Framingham Risk Atheroma Imaging Lifetime CV Risk 4 cases
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationClare Stevens. Dr Ross Keenan
Dr Ross Keenan Radiologist & Director Christchurch Radiology Group Christchurch Clare Stevens Chief CT Technologist Pacific Radiology Christchurch 14:00-14:55 WS #112: What You Need to Know re Modern Cardiac
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationUnderstanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationDisclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?
Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Duncan Churchill Royal Sussex County Hospital, Brighton COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Duncan Churchill
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More informationFractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationDavid A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio
1 STABLE ISCHEMIC HEART DISEASE: A NON-INVASIVE CARDIOLOGIST S PERSECTIVE 2018 Cardiovascular Course for Trainees and Early Career Physicians APRIL 20, 2018 David A. Orsinelli, MD, FACC, FASE Professor,
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationHow to investigate (Cardiac) Chest Pain
RCP UPDATE IN MEDICINE 27 th November 2017 How to investigate (Cardiac) Chest Pain Justin Carter Consultant Cardiologist North Tees and Hartlepool NHS Trust The spectrum of coronary disease No Disease
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationHYPERTENSION AND HEART FAILURE
HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationDevelopment and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
open access Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study Julia Hippisley-Cox, 1 Carol Coupland, 1 Peter Brindle
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More information2013 Lipid Guidelines Practical Approach. Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS
2013 Lipid Guidelines Practical Approach Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS EVIDENCE BASED MEDICINE Case #1 - LB 42 yo Asian/American female who was
More informationTesting the Asymptomatic CAD Patient: When and Why?
Testing the Asymptomatic CAD Patient: When and Why? Timothy M. Bateman M.D. Co-Director, Cardiovascular Radiologic Imaging Mid America Heart Institute Professor of Medicine University of Missouri-Kansas
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationEthnic group differences in CVD risk estimates using JBS2 and QRISK2 risk scores. Dr Andrew R H Dalton
Ethnic group differences in CVD risk estimates using JBS2 and QRISK2 risk scores Dr Andrew R H Dalton Cardiovascular Diseases CVD & Ethnic inequalities Standardised mortality ratios (SMR) for heart disease
More informationGetting serious about preventing cardiovascular disease
Getting serious about preventing cardiovascular disease Southwark s Experience Professor Kevin Fenton Director of Health and Wellbeing, London Borough of Southwark February 2018 Twitter: @ProfKevinFenton
More informationRESEARCH. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2 Julia Hippisley-Cox, professor of clinical epidemiology and general practice, 1 Carol Coupland, senior
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationCardiovascular Risk Assessment and Management Making a Difference
Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014 Numbers and age-standardised mortality rates from all causes, by sex, 1950 2010 Death rates halved Life expectancy
More informationQDScore 2011 Annual Update Information
QDScore 2011 Annual Update Information Revision History Revision date Document Version Summary of Changes 01 Jan 2011 V1.0 First issue. Contents 1 Purpose of document... 1-3 2 Rational for annual updates...
More informationNew Stable Chest Pain Guidance in the UK NICE to have, difficult to implement
New Stable Chest Pain Guidance in the UK NICE to have, difficult to implement Dr Tim Fairbairn MBChB, MRCP, PhD Consultant Imaging Cardiologist Liverpool Heart and Chest Hospital, United Kingdom 2010 Risk
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationWhat s new in cardiovascular disease risk assessment and management for primary care clinicians
Cardiovascular system What s new in cardiovascular disease risk assessment and management for primary care clinicians The recently released 2018 Cardiovascular Disease Risk Assessment and Management for
More informationRADIATION HEART DISEASE: MANAGEMENT STRATEGIES
RADIATION HEART DISEASE: MANAGEMENT STRATEGIES AMMAR CHAUDHARY MBChB, ABIM, FRCPC ASSOCIATE CONSULTANT CARDIOLOGIST KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER - JEDDAH Scope of the Problem ~ 50
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationNew Paradigms in Predicting CVD Risk
New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease
More informationDr Chris Ellis. Consultant Cardiologist Auckland City Hospital Auckland. 11:30-12:00 ECGs for Nurses, and The Basics of CT Heart Scanning
Dr Chris Ellis Consultant Cardiologist Auckland City Hospital Auckland 11:30-12:00 ECGs for Nurses, and The Basics of CT Heart Scanning ECGs for Nurses, and the Basics of CT Heart Scanning Dr Chris Ellis
More informationHelen Williams Consultant Pharmacist for CV Disease - South London
Helen Williams Consultant Pharmacist for CV Disease - South London CVD remains the leading cause of death in the UK Accounts for a third of all deaths 46,000 deaths in people < 75 years (70% of these
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationVolume 2; Number 11 July 2008
Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationEconomically efficient approaches to address chronic disease in developing countries
Economically efficient approaches to address chronic disease in developing countries Thomas A. Gaziano MD MSc Division of Cardiovascular Medicine Brigham & Women s Hospital Harvard Medical School Center
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationEuroPrevent 2010 Fatal versus total events in risk assessment models
EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationProf Rob Doughty Heart Foundation Chair Heart Health University of Auckland. Dr Fraser Hamilton. General Practitioner Heart Foundation Hamilton
Prof Rob Doughty Heart Foundation Chair Heart Health University of Auckland Dr Fraser Hamilton General Practitioner Heart Foundation Hamilton 14:00-14:55 WS #49: Controversies in Cardiovascular Disease
More information4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose
DYSLIPIDEMIA CASES Mary Malloy, MD I have nothing to disclose 1 Case 1 A 24 year old healthy, slender woman is referred because she has a family history of premature CAD (mother, age 59, had onset of angina
More informationBeyond Framingham: Risk Assessment & Treatment for Primary Prevention
Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationMOHAMMED R. ESSOP DIVISION OF CARDIOLOGY CH-BARAGWANATH HOSPITAL
MOHAMMED R. ESSOP DIVISION OF CARDIOLOGY CH-BARAGWANATH HOSPITAL DEFINITION OF A SCREENING TEST TESTING FOR A DISEASE OR CONDITION IN ASYMPTOMATIC PERSONS TO IDENTIFY THE CONDITION BEFORE IT MANIFESTS
More informationWeintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
More informationKey causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:
Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationCardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital
Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital Death By Cause - Women 2004 UK Death by Cause-Women 2004 UK -CVD is responsible
More informationChest Pain. Dr Robert Huggett Consultant Cardiologist
Chest Pain Dr Robert Huggett Consultant Cardiologist Outline Diagnosis of cardiac chest pain 2016 NICE update on stable chest pain Assessment of unstable chest pain/acs and MI definition Scope of the
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationDr Ross Keenan. Neuroradiologist Christchurch Hospital. Dr Clive Low Cardiologist
Dr Ross Keenan Neuroradiologist Christchurch Hospital Dr Clive Low Cardiologist Heart Vision Non Invasive Cardiac Imaging A Guide for Dummies Drs Clive Low (Cardiology) & Ross Keenan (Radiology) GP CME,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More information22. Cardiovascular disease
22. Cardiovascular disease What is cardiovascular disease (CVD)? What conditions does the term CVD include? What is the aetiology of CVD? What are the risk factors for CVD? How do you assess the absolute
More informationOverview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar
Overview 1. Why hypertension is important? 2. What are basic principles in treatment? 3. Different ways of measuring 4. Hypercholesterolemia NOT A REPETION OF LOCAL GUIDELINE CVD risk factors? Non modifiable
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationFORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016
FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.
More information